Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
    • The Flipside
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • From JHM
  • Industry Content
    • Patient Monitoring with Tech
An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
    • The Flipside
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • From JHM
  • Industry Content
    • Patient Monitoring with Tech

Search

1082 results

  • 1
    News

    Dapagliflozin benefits low-EF heart failure regardless of diuretic dose: DAPA-HF

    • Steve Stiles

    June 26, 2020

    The trial that turned an SGLT2 inhibitor into a heart failure drug also has clues to mechanisms behind the observed benefits. Contrary to early speculation, diuresis may be off the list.

  • 1
    News

    DAPA-HF: Dapagliflozin slows T2D onset in heart failure patients

    • Mitchel L. Zoler, PhD

    June 16, 2020

    In the landmark DAPA-HF trial that enrolled HFrEF patients without diabetes, treatment with dapagliflozin cut incident type 2 diabetes by a relative 32%.

  • News

    FDA okays emergency use for Impella RP in COVID-19 right heart failure

    • Patrice Wendling

    June 2, 2020

    The authorization allows use of the temporary heart pump in the treatment of right heart failure or decompensation, including pulmonary embolism, caused by COVID-19 complications.

  • News

    FDA approves dapagliflozin for low-EF heart failure

    • Steve Styles

    May 7, 2020

    The approval based on DAPA-HF makes dapagliflozin (Farxiga) the only drug in its class to be indicated for heart failure in the absence of diabetes.

  • 1
    News

    Tools for preventing heart failure

    • Bruce Jancin

    February 13, 2020

    SNOWMASS, COLO. – “There will be more than 1 million new cases of heart failure this year, and the vast majority of them could have been prevented.” – Gregg C. Fonarow, MD

  • 1
    News

    Treatment of heart failure with preserved ejection fraction is a work in progress

    • Doug Brunk

    January 13, 2020

    Although the disorder has a lower mortality than heart failure with reduced ejection fraction, it places a significant burden on health care systems.

  • 1
    News

    New heart failure trial data presage guideline revisions

    • Mitchel L. Zoler, PhD

    December 9, 2019

    PHILADELPHIA – Recent trial findings for sacubitril/valsartan and dapagliflozin in heart failure patients provide a blueprint for guideline changes.

  • 1
    News

    FDA adds diabetic kidney disease, heart failure indications to canagliflozin

    • Lucas Franki

    September 30, 2019

    This marks the first time in 20 years that a drug has been indicated for diabetic kidney disease treatment, according to the manufacturer.

  • News

    Machine learning–derived risk score predicts heart failure risk in diabetes patients

    • Andrew D. Bowser

    September 22, 2019

    Highest WATCH-DM scores linked to 5-year heart failure risk approaching 20%.

  • News

    Drug doses for heart failure could possibly be halved for women

    • Randy Dotinga

    September 12, 2019

    Women reached the highest level of drug efficacy at half the doses of ACE inhibitors or ARBs and beta-blockers needed by men to reach the same level.

Previous1 … 3 4 5 6 7 … 109Next
Advanced Filters
 - 
Clear All
  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
  • Copyright © 2026 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies.
    ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • Cookie Preferences